This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lévy, P. Articles by Vidaud, D. Search for Related Content PubMed PubMed Citation Articles by Lévy, P. Articles by Vidaud, D.

Molecular Profiles of Neurofibromatosis Type 1-Associated Plexiform Neurofibromas

Identification of a Gene Expression Signature of Poor Prognosis

¹ Laboratoire de Génétique Moléculaire - UPRES EA 3618, Faculté des Sciences Pharmaceutiques et Biologiques, Université Paris V, Paris; ² Laboratoire d’Oncogénétique - Institut National de la Santé et de la Recherche Médicale E 0017, Centre René Huguenin, St-Cloud; and Départements ³ d’Anatomo-Cytopathologie et de ⁴ Dermatologie, AP-HP and Université Paris XII, Hôpital Henri-Mondor, Créteil, France

Purpose: Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder with a complex variety of clinical symptoms. The hallmark of NF1 is the development of heterogeneous benign neurofibromas, which may appear as dermal neurofibromas or plexiform neurofibromas. NF1 patients with plexiform neurofibromas are at risk of developing malignant peripheral nerve sheath tumors.

Experimental Design: To obtain additional insight into the molecular pathogenesis of plexiform neurofibromas, we used real-time quantitative reverse transcription-PCR assays to quantify the mRNA expression of 349 selected genes in plexiform neurofibromas in comparison with dermal neurofibromas and patient-matched malignant peripheral nerve sheath tumors.

Results: Thirty genes were significantly up-regulated in plexiform neurofibromas compared with dermal neurofibromas. None were down-regulated. The up-regulated genes mainly encoded transcription factors and growth factors and secreted proteins, cytokines, and their receptors, pointing to a role of paracrine and autocrine signaling defects in the genesis of plexiform neurofibromas. We also identified a gene expression profile, based on MMP9, FLT4/VEGFR3, TNFRSF10B/TRAILR2, SHH, and GLI1, which discriminated those plexiform neurofibromas most likely to undergo malignant transformation.

Conclusion: Our study has identified a limited number of signaling pathways that could be involved, when altered, in plexiform neurofibroma development. Some of the up-regulated genes could be useful diagnostic or prognostic markers or form the basis of novel therapeutic strategies.

This article has been cited by other articles:

				S. Puget, J. Grill, A. Valent, I. Bieche, C. Dantas-Barbosa, A. Kauffmann, P. Dessen, L. Lacroix, B. Geoerger, B. Job, et al. Candidate Genes on Chromosome 9q33-34 Involved in the Progression of Childhood Ependymomas J. Clin. Oncol., April 10, 2009; 27(11): 1884 - 1892. [Abstract] [Full Text] [PDF]

				G. Ambrosini, H. S. Cheema, S. Seelman, A. Teed, E. B. Sambol, S. Singer, and G. K. Schwartz Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells Mol. Cancer Ther., April 1, 2008; 7(4): 890 - 896. [Abstract] [Full Text] [PDF]

				K. K. Mantripragada, G. Spurlock, L. Kluwe, N. Chuzhanova, R. E. Ferner, I. M. Frayling, J. P. Dumanski, A. Guha, V. Mautner, and M. Upadhyaya High-Resolution DNA Copy Number Profiling of Malignant Peripheral Nerve Sheath Tumors Using Targeted Microarray-Based Comparative Genomic Hybridization Clin. Cancer Res., February 15, 2008; 14(4): 1015 - 1024. [Abstract] [Full Text] [PDF]

				P. Levy, H. Ripoche, I. Laurendeau, V. Lazar, N. Ortonne, B. Parfait, K. Leroy, J. Wechsler, I. Salmon, P. Wolkenstein, et al. Microarray-Based Identification of Tenascin C and Tenascin XB, Genes Possibly Involved in Tumorigenesis Associated with Neurofibromatosis Type 1 Clin. Cancer Res., January 15, 2007; 13(2): 398 - 407. [Abstract] [Full Text] [PDF]